Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group

• DOI: 10.1371/journal.pone.0094495
• Publication Date: 2014-05-01T14:30:28Z
• Authors: Dineke Frentz; David van de Vijver; Ana Abecasis; Jan Albert; Osamah Hamouda; Louise Jørgensen; Claudia Kücherer; Daniel Struck; Jean-Claude Schmit; Jurgen Vercauteren; Birgitta Åsjö; Claudia Balotta; Colm Bergin; Danail Beshkov; Ricardo Camacho; Bonaventura Clotet; Algirdas Griskevi...; Zehava Grossman; Andrzej Horban; Tatjana Kolupajeva; Klaus Korn; Leondios Kostrikis; Kirsi Liitsola Ma...; Claus Nielsen; Dan Otelea; Dimitrios Paraskevis; Roger Paredes; Mario Poljak; Elisabeth Puchham...; Anders Sönnerborg; Danica Stanekova; Maja Stanojevic; Anne-Mieke Vandamme; Charles Boucher; Annemarie Wensing
• Keywords: HIV drug resistance

Background In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends transmitted resistance mutations (TDRM) relation the risk behaviour reported. Methods HIV-1 patients newly diagnosed 27 countries from 2002 through 2007 were included. Inclusion was representative group and geographical distribution participating Europe. Trends over calculated by logistic regression. Results From 4317 included, majority men-having-sex-with-men -MSM (2084, 48%), followed heterosexuals (1501, 35%) injection users (IDU) (355, 8%). MSM more often Western Europe origin, infected with subtype B virus, recently (<1 year) (p<0.001). The prevalence TDRM highest (prevalence 11.1%), (6.6%) IDU (5.1%, p<0.001). predominantly ascribed nucleoside reverse transcriptase inhibitors (NRTI) 6.6% MSM, 3.3% 2.0% (p = 0.001). A significant increase non- (NNRTIs) decrease protease observed 0.008 p 0.006, respectively), but not heterosexual 0.68 0.14, respectively). Conclusions showed have significantly higher compared IDU. increasing NNRTI is likely negatively influence therapy response first-line therapy, as most include drugs.